Dear Dr. Chaudry:

Please refer to your June 17, 2005 supplemental new drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Detrol (tolterodine tartrate), 1 and 2 mg tablets. This supplement provided a revised package insert (PI) in response to the Division’s “Prior Approval Supplement Request” letter, dated May 18, 2005.

We completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the patient package insert).

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved supplement NDA 20-771/S-013.” Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Jean Makie, M.S., R.D., Sr. Regulatory Project Manager, at 301-796-0952

Sincerely,

{See appended electronic signature page}

Daniel Shames, M.D.
Director,
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Daniel A. Shames
10/17/2005 04:57:36 PM